Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020 - Scorecard - MDSpire
Advertisement
Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020
Clinical Scorecard: Establishing a Safe Surgical Management Threshold for Vena Cava Thrombus in Patients with Renal Cell Carcinoma: Insights from a Comprehensive Analysis of 3,700 Cases in Germany (2006-2020)
At a Glance
Category
Detail
Condition
Renal cell carcinoma (RCC) with vena cava tumor thrombus (RCCTT)
Key Mechanisms
Tumor thrombus extension into vena cava requiring radical nephrectomy with cavotomy and thrombus extirpation; possible need for extracorporeal circulation and vena cava replacement
Target Population
Patients with non-metastatic advanced RCC presenting with vena cava tumor thrombus
Care Setting
High-volume specialized surgical centers with interdisciplinary teams and equipped intensive care units
Key Highlights
Radical nephrectomy with vena cava thrombus resection is the only curative treatment for RCC with vena cava thrombus.
Higher hospital surgical caseload (>9 cases/year) is associated with significantly lower in-hospital mortality (2.3%) compared to low caseload centers.
Perioperative blood transfusion rates and length of hospital stay have decreased over time, with surgical approach and hospital volume influencing outcomes.
Guideline-Based Recommendations
Diagnosis
Identify RCC with vena cava tumor thrombus using ICD-10 coding and clinical staging.
Assess tumor thrombus extent to plan surgical approach.
Management
Perform radical nephrectomy with cavotomy and thrombus extirpation as curative treatment.
Use extracorporeal circulation when thrombus extends into right cardiac atrium.
Replace vena cava with alloplastic material if vena cava wall resection is necessary.
Prefer treatment in high-volume centers with experienced interdisciplinary teams.
Track length of hospital stay and ventilation time as indicators of recovery.
Observe in-hospital mortality rates, especially in relation to hospital caseload.
Risks
High risk of extensive bleeding and pulmonary embolism during surgery.
Increased mortality and complication rates in low-volume centers.
Potential need for extracorporeal circulation increases procedural complexity.
Patient & Prescribing Data
3,700 surgical cases of RCC with vena cava tumor thrombus in Germany from 2006 to 2020
Stable annual surgery numbers with increasing treatment concentration in higher volume centers; transperitoneal approach usage increased; extracorporeal circulation required in 5.6% of cases; blood transfusion rates decreased over time.
Clinical Best Practices
Centralize surgical management of RCC with vena cava thrombus in high-volume hospitals (>9 cases/year) to reduce mortality.
Utilize transperitoneal surgical approach preferentially due to increased usage and outcomes.
Prepare for potential extracorporeal circulation in cases with thrombus extension into cardiac atrium.
Ensure availability of interdisciplinary surgical teams and equipped intensive care units.
Monitor ventilation time closely as it strongly influences length of hospital stay and mortality.
by Thomas Martin, Johannes Huber, Rainer Koch, Marius Butea-Bocu, Lennard Haak, Luka Flegar, Matthias Giese, Fabian Kormann, Cem Aksoy, Aristeidis Zacharis, Christer Groeben
CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2024.